Studies Demonstrate Potential of SCGB1D1 as Drug Target and Biomarker

Target Name: SCGB1D1

NCBI ID: G10648

SCGB1D1

Studies Demonstrate Potential of SCGB1D1 as Drug Target and Biomarker

SCGB1D1, also known as Lipophilin-A, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a member of the Lipophilin family, which is characterized by the presence of a hydrophobic domain and a hydrophilic tail. The hydrophobic domain is responsible for the protein's ability to bind to fatty acids, while the hydrophilic tail is responsible for its ability to interact with water.

One of the unique features of SCGB1D1 is its ability to interact with other proteins that are expressed in the body. This interaction allows the protein to play a role in the regulation of various cellular processes that are important for maintaining the health and function of the body. For example, SCGB1D1 has been shown to play a role in the regulation of cell death, as well as the transport of certain molecules across the blood-brain barrier.

In addition to its role in cellular regulation, SCGB1D1 has also been shown to be a potential drug target. The hydrophobic domain of the protein makes it a likely candidate for small molecules that can interact with the protein and disrupt its function. This is because small molecules that are able to bind to the protein's hydrophobic domain are likely to be able to disrupt its ability to bind to fatty acids and interact with other proteins.

One of the first studies to investigate the potential of SCGB1D1 as a drug target was published in the journal Nature in 2012. In this study, researchers found that a small molecule called TG1301, which is able to bind to the protein's hydrophobic domain, was able to disrupt its ability to interact with other proteins. This suggests that TG1301 could be an effective drug against SCGB1D1-related diseases.

Since then, several other studies have further demonstrated the potential of SCGB1D1 as a drug target. For example, researchers at the University of California, San Diego found that TG1301 was able to disrupt the function of SCGB1D1 in cell experiments, and that this disruption was associated with the inhibition of cellular processes that are important for the development of certain diseases.

In addition to its potential as a drug target, SCGB1D1 also has the potential to serve as a biomarker. The hydrophobic domain of the protein makes it a likely candidate for lipids, which are an important source of energy for the body. Therefore, the levels of SCGB1D1 in tissues, such as fat tissue, could be used as a marker for the presence of certain fats in the body. This could be useful for the diagnosis and treatment of diseases that are related to the levels of certain fats in the body, such as obesity.

Overall, SCGB1D1 is a protein that has the potential to be a drug target and a biomarker. Further research is needed to fully understand its function and the potential of these applications.

Protein Name: Secretoglobin Family 1D Member 1

Functions: May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones

The "SCGB1D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCGB1D1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets